Medical Device | January 25, 2022
Agilent announces the Innovative Seahorse XF Pro Analyzer
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
Go-ahead for pivotal clinical trial which is expected to commence by March
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
Previously, the use of the drug was limited to patients requiring hospitalization
UCB plans to submit regulatory applications in Q3 2022
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Subscribe To Our Newsletter & Stay Updated
